The physician-led practice manager has abolished over $1.5bn in patient debt via Cascade365 and non-profit Undue Medical Debt, targeting low-income patients.

The Cambridge DDR biotech has appointed a Chief Business Officer, General Counsel, and VP of Regulatory Affairs ahead of a potential US commercialisation push.

Avacta's Science Day 2026 showcased tumour-selectivity and dual-payload data positioning its PDC platform ahead of approved ADCs.

Abdakibart met HiSCR75 at both doses in the 253-patient LOTUS trial, with Avalo now planning a registrational Phase 3 programme in hidradenitis suppurativa.

Avalyn will show poster data on inhaled pirfenidone nebuliser usability and patient-centred supportive care in pulmonary fibrosis at ATS in Orlando.

BEYONTTRA becomes the first near-complete TTR stabiliser approved in Brazil, backed by Phase 3 data showing a 42% cut in cardiovascular mortality and hospitalisation.

The Durham-based medical-technology company reported Q1 net sales of $132.1m and lifted its full-year adjusted EPS and cash-flow forecasts.

Bioxodes presented final BIRCH trial data at ESOC 2026, showing BIOX-101 reduced haemorrhage volume and edema growth with no mortality in 23 ICH patients.

BriaCell Therapeutics can now initiate a Phase 1/2a study of its next-generation personalised cell immunotherapy in metastatic breast cancer.

CDT Equity has filed for PCT patent protection on its myeloperoxidase inhibitor AZD5904 and is now actively seeking an out-licensing partner for late-stage

Phase 2b CLOVER WaM data show 83.6% ORR and 17.8-month median response duration, strengthening the case for accelerated FDA approval.

Austin-based Cristcot has hired a former Shorla Oncology CCO to head commercial preparations for its FDA-pending ngHCA suppository.